April 30, 2026 Diginex Issues Corporate Update Highlighting Strategic AI Transformation, $1.5 Billion Resulticks Acquisition with Strong EBITDA Profile of US$46–50 Million, and Disciplined Funded Growth Strategy
April 30, 2026 Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
April 30, 2026 Selerix and RightPath Benefits Announce Strategic Partnership to Strengthen ACA Compliance for High-Turnover Workforces
